The Trump administration on Monday announced a second group of pharmaceutical companies had pledged to lower drug prices to levels comparable to those in other nations.

But the details of the deals, which President Trump has touted from the White House as one of the most important breakthroughs in health care, aren’t public. Some key questions remain — including whether all the companies in the second wave would avoid tariffs or otherwise mandatory Medicare drug pricing pilot programs. (The White House did not respond to requests for comment about these questions.)

Here are some of the biggest questions about the agreements.

Continue to STAT+ to read the full story…